Tango Therapeutics, a biotechnology firm, stands out due to its unique approach to cancer treatment, utilizing advances in DNA sequencing and CRISPR-based target discovery to develop novel medicines targeting cancer vulnerabilities. The company's focus on synthetic lethality, a method that targets specific genes in cancer cells leaving normal cells largely unaffected, offers a potential for enhanced anti-tumor efficacy and reduced toxicity. Furthermore, Tango's patient-centric approach and deep understanding of genetic subtypes of cancer enable it to identify novel drug targets and combinations, accelerating the development of transformational new therapies for patients with well-defined populations currently lacking effective treatment options.